Breakfast Technical Briefing on Medical Equipment Stocks -- Abbott Laboratories, Boston Scientific, Edwards Lifesciences, and Medtronic

Tuesday, October 10, 2017 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 10, 2017 /PRNewswire/ --

If you want a Stock Review on ABT, BSX, EW, or MDT then come over to

and sign up for your free customized report. Medical Appliances and Equipment companies engage in the manufacture of medical instruments such as dental and surgical appliances. Most of the time, these companies are structured as corporations. Pre-market
today, monitors Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Edwards Lifesciences Corp. (NYSE: EW), and Medtronic PLC (NYSE: MDT). Daily Stock Tracker published free research reports on these stocks today at:

Abbott Laboratories 

North Chicago, Illinois headquartered Abbott Laboratories' shares declined 0.62%, closing Monday's trading session at $54.66. The stock recorded a trading volume of 3.99 million shares. The Company's shares have advanced 5.07% in the last month, 13.52% over the previous three months, and 42.31% since the start of this year. The stock is trading 7.35% above its 50-day moving average and 18.40% above its 200-day moving average. Additionally, shares of Abbott Labs, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 69.62.  

On September 20th, 2017, Abbott Labs announced that it will report its Q3 2017 financial results on October 18th, 2017, before the market opens. The announcement will be followed by a conference call at 9:00 a.m. ET. The live webcast of the call will be accessible on the Company's Investor Relations website.

On October 06th, 2017, research firm JP Morgan resumed its 'Neutral' rating on the Company's stock. See our free and comprehensive research report on ABT at:

Boston Scientific 

On Monday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. recorded a trading volume of 4.34 million shares. The stock declined 0.58%, ending the day at $29.33. The Company's shares have advanced 1.88% in the past month, 6.54% in the previous three months, and 35.60% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.53% and 12.42%, respectively. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 64.11.  

On October 04th, 2017, Boston Scientific (BSX) announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel, and corporate secretary. Ralls-Morrison will join BSX on November 30th, 2017 as a member of the executive committee, with responsibility for providing legal counsel across the Company's global businesses and functions, and overseeing its global compliance function. BSX free research report is just a click away at:

Edwards Lifesciences 

Irvine, California headquartered Edwards Lifesciences Corp.'s stock finished the day 1.11% lower at $110.22 with a total trading volume of 854,414 shares. The Company's shares have advanced 17.63% on an YTD basis. The stock is trading above its 200-day moving average by 4.32%. Additionally, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 45.70. Sign up for your complimentary report on EW at:


Shares in Dublin, Ireland headquartered Medtronic PLC ended yesterday's session 3.61% lower at $76.93. The stock recorded a trading volume of 12.76 million shares, which was above its three months average volume of 4.78 million shares. The Company's shares have advanced 8.00% since the start of this year. The stock is trading 5.33% below its 50-day moving average. Moreover, shares of Medtronic, which manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide, have an RSI of 33.78.  

On September 12th, 2017, Medtronic announced the global launch of the StealthStation[TM] ENT, a new surgical navigation system designed for surgeons treating conditions within the ear, nose, and throat anatomy. The Company has received US Food and Drug Administration 510k clearance and CE (Conformité Européenne) Mark for the system.

On October 09th, 2017, research firm Stifel reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $91 a share to $83 a share. Register for free on and download the latest research report on MDT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store